36% of patients with refractory systemic lupus erythematosus (SLE or lupus) remain well after undergoing B-cell depletion therapy (BCDT) without needing further standard immunosuppressive agents, according to a study presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.
Get the full story...
